Clinically Vulnerable Families πŸ’™πŸ’œπŸ’— Profile picture
Jan 21 β€’ 23 tweets β€’ 8 min read β€’ Read on X
🚨Dame Kate Bingham🚨
Dubbed the "hero in a pink jacket πŸ’•"

On Evusheld:
"I felt very strongly [.]. We were following a very clear 2 tier strategy where the CV immunocompromised were being deprioritised [.] I felt that was *manifestly* wrong both ethically and morally [.]"
1/🧡
The above video was taken out of sequence. The below should give more context...

KB "So actually, the first goal was around protecting the UK population."

CTI [Hugo Keith KC]
"Do you think you succeeded on securing or making available those monoclonal antibodies?"

KB "No!"
2/
Kate goes on to make the argument that by not protecting this population, we were also promoting viral mutation and the evolution of variants.

3/
On funding, clinical trials, and onshore manufacturing. We need long-term planning and strategy.

KB "We don't have that level of capability or long-term thinking in government."

4/
On the inclusion of therapeutics within the remit of the Vaccine Taskforce:

KB "It was quite clear that there was 'open warfare' between BEIS [Department for Business, Energy & Industrial Strategy] and the Department for Health"

5/
CTI "If you had brought [.] therapeutics within the remit of the VTF, you might have ended up dividing your attention [.] You would have been less able to focus ruthlessly on the question of identifying, procuring, and making available vaccines [.]"

KB "Correct"
6/
KB "I felt strongly that we should have governance over the neutralising antibodies because there are a portion on people in the UK who are immunocompromised."

"It was part of our original mandate."

"to protect all those people *including* the immunocompromised."

7/
She goes on to explain the difference between the antibodies and how Evusheld was designed to last longer to dose every 6m minimum. Other antibodies, designed as treatments, only last around 1 month.

8/
If the VTF had taken on antivirals, Kate believes that they could have made treatments available more rapidly, and they might have been more effective. However, she would have required a larger team.

9/
CTI "Did you ever get the impression during your time in the VTF that the issue of prophylactic development was being left behind, being made to be a second-class citizen?"

KB " I absolutely felt that, yes. From late October 2020."

10/
The JCVI identified *30 MILLION* people who were deemed to be Clinically Vulnerable (at that time):

πŸ’™All adults over 50
πŸ’œThose under 50 with severe underlying disease

Kate described it as an "enhanced 'flu cohort"

11/
"Immediately" in May 2020, the VTF were aware of the development of Evusheld.

12/
KB "We initially signed a [.] letter of intent, but non-binding for a million doses of their long acting antibody cocktail [.] expected to have a 6m effect."

13/
1 million doses of Evusheld =

2 doses spread over 1 year
OR
1 dose per winter for 2 winters

"The numbers of immunocompromised people [500k] were data that had come from the Department of Health."

14/
AZ couldn't supply this order, as they had 2.5M doses for the world.

They then asked what was the minimum order to protect the immunocompromised population.

15/
The CMOs suggested no more than 50,000 if there was a political will.

Ultimately, no prophylactic treatment has *ever* been purchased to protect this, our most vulnerable, population.

16/
KB "I felt very strongly [.]. We were following a very clear 2 tier strategy where the CV immunocompromised were being deprioritised [.] 1 felt that was *manifestly* wrong both ethically and morally [.]"

17/
KB " It did not follow the goal that we had been set, which was to protect the entire population."

18/
Important comparison between the attitude to procuring vaccines vs. prophylactic treatments for people who are not sufficiently protected by vaccines.

19/
CTI suggests that the cost of Evusheld was not the reason for the decision against.

Kate quotes JVT, "I consider cost, including cost effectiveness and practicality considerations to be entirely rational factors when making decisions on neutralising Ab procurement."

20/
🧨πŸ’₯

Thank you πŸ’• @katebingham2 πŸ’•

"The fact that the vaccine rollout had been effective doesn't stop people without an immune system getting infected."

21/
The decision about purchasing Evusheld was ultimately with ministers.

22/
Kate Bingham on that lack of purchase of Evusheld:

"I just think that it was the wrong decision."

23/

β€’ β€’ β€’

Missing some Tweet in this thread? You can try to force a refresh
γ€€

Keep Current with Clinically Vulnerable Families πŸ’™πŸ’œπŸ’—

Clinically Vulnerable Families πŸ’™πŸ’œπŸ’— Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cv_cev

Jan 17
πŸ’₯Clinically Vulnerable Families πŸ’₯

Yesterday, @lara_wong, took the stand as founder and leader of CVF.
**Sorry for the delay!**

- New risks posed by Covid-19
- We need to be recognised as an equality group.

1/ FOLLOW THIS THREAD
Clinically Vulnerable people were, and are still, being let down.

2/
The lack of infection prevention and control in vaccination centres for an airborne virus was very concerning.

3/
Read 21 tweets
Dec 28, 2024
πŸ’Š Important 🧡 - 'flu antivirals πŸ’Š

Here’s a quick thread on what you need to know about accessing antivirals for treatment and prevention in the UK.

1/ Image
When are antivirals recommended?

Antivirals are advised for:
πŸ’™πŸ’œπŸ’— High-risk groups (see list below)
πŸ₯ People with severe symptoms or those hospitalised.

Early action is vital!

2/ Risk factors for complicated influenza  These include:  neurological, hepatic, renal, pulmonary and chronic cardiac disease  diabetes mellitus  severe immunosuppression  age over 65 years  pregnancy (including up to 2 weeks post-partum)  children under 6 months of age  morbid obesity (BMI β‰₯40)
The 'severe immunosuppression' group is different again, but this list is "not comprehensive".

If you think you may qualify as Clinically Vulnerable to 'flu, it is always worth asking.

3/ 5. Severe immunosuppression  Examples of severe immunosuppression relevant to this guidance are given below. Degrees of immunosuppression are difficult to quantify and individual variation exists, therefore this list is not comprehensive. Examples of severe immunosuppression include:  severe primary immunodeficiency  current or recent (within 6 months) chemotherapy or radiotherapy for malignancy.  solid organ transplant recipients on immunosuppressive therapy  bone marrow transplant recipients currently receiving immunosuppressive treatment, or within 12 months of receiving immunosuppressio...
Read 8 tweets
Nov 27, 2024
🚨Clinically Vulnerable Families - closing
** Shared in full**

Thanks to the @covidinquiryuk staff & team

"The vast majority of people who died [.] were Clinically Vulnerable [.] including people who caught Covid-19 in hospitals, which were supposed to be places of safety."

1/
"Most urgently, we need to make healthcare safe for Clinically Vulnerable people."

"And by making it safe for them - by improving ventilation and putting in place other protective measures - we make it safe for others too."

2/
πŸ›‘Shielding

CEV people are a diverse group with varied personal circumstances.

It provided a passport:
🏠 Right to work from home
πŸ’· SSP entitlement
🚚 Food & medicine deliveries
πŸ’‰ Priority vaccine access

3/
Read 28 tweets
Nov 27, 2024
🚨 British Medical Association - closing

"aging estates meant that infection control measures could not always be fully implemented."
- Large open bays
- Inability to distance
- Lack of side rooms for isolating patients
- Lack of ventilation

1/
"The inquiry proceedings have laid bare the catastrophic consequences that are destined to be repeated without fundamental change."

2/
"healthcare workers were at higher risk of contracting Covid-19."

"The Health and Safety Executive [failed] to challenge adequacy of the IPC guidance, to act on concerns raised by [the BMA], and to ensure that employers compied with their health and safety responsibilities."

3/
Read 10 tweets
Nov 26, 2024
🚨 @cymru_inquiry Covid Bereaved🏴󠁧󠁒󠁷󠁬󠁳󠁿
Anne-Louise Marsh-Rees, Co-Leader.
Great witness!

🩺Symptoms were unclear
πŸ›‘Shielding comm confusing
⛔️Protect the NHS

Please do look at this whole 🧡
1/
No communication with the people who were affected. They have had to work hard to lobby for changes.

2/
IPC guidelines weren't questioned when there was outbreak after outbreak.

Traffic lighting of wards for Covid+ patients and non Covid+ not adhered to.

3/
Read 7 tweets
Nov 16, 2024
Who will get a Covid booster in 2025? Far fewer than before...

The JCVI decision means that Clinically Vulnerable people u70 and who aren't immunosuppressed lose access.

β€œCost-effectiveness” prioritised over protection.

NEW CONCERNING STUDY πŸ‘‡

1/🧡 Adult eligibility  Adult eligibility should be based on the willingness-to-pay approach that is subject to procurement and delivery at a cost-effective price. The advice for universal vaccination from age 75 years is an example. JCVI has no role in the procurement or delivery of COVID-19 vaccines or any other vaccine.
Until now, Covid vaccine policy prioritised protecting 'at risk' groups.

Their approach focuses on β€œcost-effectiveness,” raising age thresholds. Not providing vaccine protection to younger Clinically Vulnerable. It’s a deeply worrying change.

This data may have been used.
2/ Fig. 3: Using data from the spring and autumn 2023 boosters and the 2023/24 winter wave of COVID-19, vaccine threshold prices stratified by age-group, risk-group and modelling approach.  We calculate the vaccine threshold price for the two time periods (top row: winter 2023/24; bottom row: spring 2023), 16 age groups (y-axis), three risk groups (panels) and five methodologies (red, dark-blue, light-blue, grey and black). Dots show the most likely value assuming Β£20,000 per QALY; when assuming Β£30,000 per QALY the extended bar-and-whisker plots show the 95%, 80% and 50% credible intervals co...
Younger Clinically Vulnerable people e.g. those with chronic heart failure, COPD, or diabetes could be excluded.

The study admits data for our group is limited, meaning the most at-risk could fall through the cracks.

*It is unclear if the study was used in decision-making.*

3/ Image
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(